Synthorx Inc (THOR) 뉴스

News: $THOR SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - THOR, ARQL, LOGM

NEW YORK, NY / ACCESSWIRE / December 24, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Synthorx , Inc. (NASDAQ:THOR) The investigation concerns whether Synthorx and its board of directors violated the federal securities law...

Find out more THOR - SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - THOR, ARQL, LOGM

News: $THOR What Happened in the Stock Market Today

Major benchmarks drifted lower Monday as uncertainty over a trade deal continued to weigh on the market. The  Dow Jones Industrial Average (DJINDICES: ^DJI)  and the  S&P 500 (SNPINDEX: ^GSPC)  closed near session lows. Data source: Yahoo! Finance. As for individual...

Read the whole news THOR - What Happened in the Stock Market Today

News: $THOR SYNTHORX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of THOR and Encourages Investors to Contact the Firm

NEW YORK , Dec. 9, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Synthorx, Inc. (NASDAQ: THOR) breached their fiduciary duties or violated the federal securities laws...

In case you are interested THOR - SYNTHORX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of THOR and Encourages Investors to Contact the Firm

News: $THOR Synthorx Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Synthorx, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - THOR

NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Synthorx, Inc. (NASDAQ: THOR) to Sanofi for $68.00 per share is fair to Synthorx shareholders. On behalf of Synthorx shareholders, Halper Sadeh LLP may seek ...

Find out more THOR - Synthorx Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Synthorx, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - THOR

News: $THOR Why Synthorx Stock Is Soaring Today

Shares of the clinical-stage biotech Synthorx (NASDAQ: THOR) jumped by an eye-popping 169% right out of the gate Monday morning. What's behind this enormous spike? Synthorx's stock is on fire today in response to an all-cash buyout agreement with French pharma giant Sanofi (NASDAQ: SNY...

Read the whole news THOR - Why Synthorx Stock Is Soaring Today

News: $THOR Monday Morning Kickoff, by 24/7 Market News

DENVER, Colo., December 9, 2019- (24/7MarketNews via COMTEX) Venture Market News for December 9, 2019. Market Trend As the US-China trade talks may continue to try to take up all the air in the room, biotech M&A activity is quietly picking up, with two high premium acquisitions in the spce...

Find out more THOR - Monday Morning Kickoff, by 24/7 Market News

News: $THOR Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology product candidate, THOR-707, will be presented...

Find out more THOR - Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress

$THOR So bad it may be good, Reversal trade into earnings

From a fundamental perspective there is not a great deal of reasons to be looking to long the stock of NYSE:THO , but it looks compelling from a technical perspective. The Momentum indicator is seen as a leading indicator and in this case it is bullish as is the RSI and Stoch . This stock has been so beaten down with the entire sector, that any positive news could result in a massive jump post earnings , while there is security from tried and tested support below. This is a risky trade but could be very rewarding.


AVERAGE ANALYSTS PRICE TARGET $76
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT

I just wanted to start a friendly discussion between SSH and THOR. I came here, as Yahoo Message board is full of false information. SSH stock has been upgraded and their working on FDA approval but Scot Trade lists Thor as a competitor of SSH. I was just wondering what is THOR working on? I don't see anything new in the news regarding it.

Catalyst behind Thoratec spike higher unclear

The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.

Any idea what is up with THOR this morning? Can't find any news, but I like what its doing.

Nice

Bounce indeed:

A number of other analysts have also recently weighed in on THOR. Analysts at Raymond James reiterated an “outperform” rating on shares of Thoratec in a research note on Thursday. They now have a $30.00 price target on the stock, down previously from $41.00. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of Thoratec in a research note on Thursday. They now have a $35.00 price target on the stock, down previously from $40.00. Finally, analysts at Oppenheimer cut their price target on shares of Thoratec from $41.00 to $35.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $37.18.

Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce Bounce bounce bounce or no?

davidaames, this is another great long-term growth stock. Not to mention the excellent balance sheet!

http://bloom.bg/1iHFPxp

Come one baby, come back to the $25 level like last month.

This stock has done quite well since this update - hope you made a bundle on it.

UPDATE: FDA Allows Wider Use Of Thoratec Heart-Pumping Device
Date : 01/20/2010 @ 4:54PM
Source : Dow Jones News
Stock : Thoratec Corp. (THOR)
Quote : 29.03 -0.49 (-1.66%) @ 7:58PM




UPDATE: FDA Allows Wider Use Of Thoratec Heart-Pumping Device

(Updated to add information on study used to support approval starting in sixth paragraph.)

By Jennifer Corbett Dooren

Of DOW JONES NEWSWIRES

WASHINGTON (Dow Jones)
The Food and Drug Administration Wednesday granted wider approval for a heart-pumping device made by Thoratec Corp. (THOR), allowing the device to be used in severely ill heart-failure patients who can't receive a heart transplant.

Until now the company's HeartMateII device had been approved for use in patients awaiting heart transplants.

The product, known as a left-ventricular assist device, is implanted inside the body and is designed to help the heart pump blood through the body. The device is run by an external battery pack that is worn around a patient's waist.

An older device, HeartMate XVE, is approved for use in heart-failure patients who aren't candidates for heart transplants, but is much larger than the newer device, and its pumping mechanism can be heard outside the body. The older HeartMate also can't be used in children or women. The new HeartMateII version is about seven times smaller and is almost silent.

The American Heart Association estimates that about 2,100 heart transplants are performed annually in the U.S., and that there are about 150,000 patients with advanced heart failure. In earlier stages of heart failure, patients are managed with medication or other devices such as defibrillators, but as the disease progresses there are few treatment options.

The approval was based on a study that compared patients receiving the HeartMateII device to patients receiving the older HeartMate XVE. The study involved 200 patients, of whom 134 were implanted with the newer device and 66 with the older device.

The main study goal looked at how many patients, after two years, remained free from a stroke or repeat surgery to replace or repair the device. After two years, 62, or 46%, of patients receiving the newer device reached the study goal, compared with 7, or 11%, of patients who received the older device.

Looking at just survival, 68% of patients with the newer device were alive one year after receiving the device, compared with 55% who received the older device. After the second year, 58% of patients with the new device were alive, compared with 24% of the patients with the older device.

The FDA said Thoratec
is being required to conduct a postapproval study to further evaluate the device's performance.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

THOR Product Recall. Thoratec is now a burnt piece of toast. Looks like it will be a penny stock now like its competitor Ventracor.

Good Short: THOR is reversing, breaking down, and failing at the downtrending 50 day moving average and the 200 day moving average, on strong volume

EMDF COLUMBUS, Ohio--(BUSINESS WIRE)--Nov. 17, 2004--E Med Future, Inc. (OTCBB:EMDF - News) is hosting a luncheon for dignitaries and Ambassadors from more than 20 African nations for a formal introduction of NeedleZap®, a device that disintegrates used injection needles at their point of use. The event will take place at the University Club of Washington this Friday, November 19, 2004, from Noon until 2:00 p.m.

Dr. Lamine Ba, Ambassador of Senegal, who recently learned about NeedleZap® and has already endorsed the product to the Senegalese Ministry of Health, was integral in the organization of the meeting. According to the most recent report from the United Nations, an estimated 25 million people are infected with HIV in Sub-Saharan Africa. Senegal, in contrast, has done well in its fight to limit the spread of HIV/AIDS. The country has an infection rate of approximately 2 percent, one of the lowest on the African continent. For that reason, Dr. Ba felt strongly that other members of the African diplomatic community should learn about NeedleZap®.

"To be effective against curtailing the spread of HIV/AIDS, you have to look at all the root causes," said Dr. Ba, E Med's Guest of Honor at the event. "The re-use of contaminated needles is just one of many problems African countries have to combat if progress is to be made against this deadly disease. That's why it's important to hold this forum where the benefits of NeedleZap® can be explained and demonstrated."

Bombs AWAY

DISCLAIMER - Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have

http://www.quicken.com/investments/strategies/?symbol=thor